PMID- 33627398
OWN - NLM
STAT- MEDLINE
DCOM- 20210517
LR  - 20221005
IS  - 1940-6215 (Electronic)
IS  - 1940-6207 (Print)
IS  - 1940-6215 (Linking)
VI  - 14
IP  - 5
DP  - 2021 May
TI  - COVID-19 Disruptions to Endoscopic Surveillance in Lynch Syndrome.
PG  - 521-526
LID - 10.1158/1940-6207.CAPR-20-0565 [doi]
AB  - Disruptions in cancer screening due to the COVID-19 pandemic may 
      disproportionally affect patients with inherited cancer predisposition syndromes, 
      including Lynch syndrome. Herein, we study the effect of the COVID-19 pandemic on 
      endoscopic surveillance in Lynch syndrome through a prospective study of patients 
      with Lynch syndrome at a tertiary referral center who were scheduled for 
      endoscopic surveillance during the COVID-19 pandemic shutdown between March 16, 
      2020 and June 4, 2020. Of our cohort of 302 individuals with Lynch syndrome, 34 
      (11%) had endoscopic procedures scheduled during the COVID-19 pandemic shutdown. 
      Of the 27 patients whose endoscopic surveillance was canceled during this period, 
      85% rescheduled procedures within 6 months with a median delay of 72 days 
      [interquartile range (IQR), 55-84 days], with identification of an advanced 
      adenoma or gastrointestinal cancer in 13%. Individuals who did not have a 
      rescheduled endoscopic procedure were significantly younger than those with a 
      rescheduled procedure [age 35 (IQR, 26-43) vs. age 55 (IQR, 43-63), P = 0.018]. 
      Male sex was also suggestive of increasing likelihood of not having a rescheduled 
      procedure. Taken together, our study demonstrates that the COVID-19 pandemic 
      shutdown led to delayed endoscopic surveillance in Lynch syndrome, with 
      potentially impactful delays among young patients. These data also emphasize the 
      importance of timely surveillance in Lynch syndrome during this current, as well 
      as potential future, global pandemics. PREVENTION RELEVANCE: The COVID-19 
      pandemic has led to unprecedented disruptions in cancer screening, which may have 
      disproportionate effects on individuals at increased cancer risk, including those 
      with Lynch syndrome. Herein, we show that the COVID-19 pandemic led to 
      significant disruptions in Lynch syndrome surveillance with potentially impactful 
      delays, thus highlighting the importance of ensuring timely surveillance among 
      this high-risk cohort.
CI  - (c)2021 American Association for Cancer Research.
FAU - McKenna, Danielle B
AU  - McKenna DB
AUID- ORCID: 0000-0002-8317-1520
AD  - Division of Hematology-Oncology, Perelman School of Medicine, University of 
      Pennsylvania, Philadelphia, Pennsylvania.
FAU - Dudzik, Christina M
AU  - Dudzik CM
AD  - Division of Gastroenterology and Hepatology, Perelman School of Medicine, 
      University of Pennsylvania, Philadelphia, Pennsylvania.
FAU - Kumar, Shria
AU  - Kumar S
AD  - Division of Gastroenterology and Hepatology, Perelman School of Medicine, 
      University of Pennsylvania, Philadelphia, Pennsylvania.
FAU - Mahmud, Nadim
AU  - Mahmud N
AD  - Division of Gastroenterology and Hepatology, Perelman School of Medicine, 
      University of Pennsylvania, Philadelphia, Pennsylvania.
AD  - Gastroenterology Section, Corporal Michael J. Crescenz VA Medical Center, 
      Philadelphia, Pennsylvania.
AD  - Leonard David Institute of Health Economics, Perelman School of Medicine, 
      University of Pennsylvania, Philadelphia, Pennsylvania.
AD  - Department of Biostatistics, Epidemiology, and Informatics, University of 
      Pennsylvania, Philadelphia, Pennsylvania.
FAU - Katona, Bryson W
AU  - Katona BW
AUID- ORCID: 0000-0001-8186-9119
AD  - Division of Gastroenterology and Hepatology, Perelman School of Medicine, 
      University of Pennsylvania, Philadelphia, Pennsylvania. 
      bryson.katona@pennmedicine.upenn.edu.
LA  - eng
GR  - R03 DK120946/DK/NIDDK NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20210224
PL  - United States
TA  - Cancer Prev Res (Phila)
JT  - Cancer prevention research (Philadelphia, Pa.)
JID - 101479409
SB  - IM
MH  - Adult
MH  - COVID-19/*epidemiology/virology
MH  - Colorectal Neoplasms, Hereditary Nonpolyposis/*diagnosis
MH  - Early Detection of Cancer/*statistics & numerical data
MH  - Endoscopy, Gastrointestinal/*statistics & numerical data
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Pennsylvania/epidemiology
MH  - Practice Patterns, Physicians'/*statistics & numerical data
MH  - Prospective Studies
MH  - SARS-CoV-2/*physiology
PMC - PMC8102358
MID - NIHMS1676598
COIS- Conflicts of Interest: SK - Boston Scientific and Olympus (travel). BWK - Janssen 
      Pharmaceuticals (travel) and Exact Sciences (consulting). No conflicts of 
      interest for the other authors.
EDAT- 2021/02/26 06:00
MHDA- 2021/05/18 06:00
PMCR- 2021/11/01
CRDT- 2021/02/25 05:35
PHST- 2020/10/30 00:00 [received]
PHST- 2020/12/15 00:00 [revised]
PHST- 2021/02/15 00:00 [accepted]
PHST- 2021/02/26 06:00 [pubmed]
PHST- 2021/05/18 06:00 [medline]
PHST- 2021/02/25 05:35 [entrez]
PHST- 2021/11/01 00:00 [pmc-release]
AID - 1940-6207.CAPR-20-0565 [pii]
AID - 10.1158/1940-6207.CAPR-20-0565 [doi]
PST - ppublish
SO  - Cancer Prev Res (Phila). 2021 May;14(5):521-526. doi: 
      10.1158/1940-6207.CAPR-20-0565. Epub 2021 Feb 24.